Indolent Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Indolent Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-06-24Clinical Trial Update: Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Clinical trial update on a Phase 1/2 study of lenalidomide in combination with obinutuzumab for relapsed indolent non-Hodgkin lymphoma, incl…
-
CLINICAL_TRIALS trial_result · 2025-06-09Clinical Trial Update: A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL [Phase 1, Phase 2]
Phase 1/2 study of ATG-010 with lenalidomide and rituximab in adults with diffuse large B-cell lymphoma and indolent non-Hodgkin lymphoma ha…
-
CLINICAL_TRIALS trial_result · 2025-05-23Clinical Trial Update: A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma [Phase 2]
Phase 2 study of blinatumomab in relapsed or refractory indolent non-Hodgkin lymphoma has been terminated. Results have been posted.
-
CLINICAL_TRIALS trial_result · 2025-05-21Clinical Trial Update: A Study of Linperlisib (YY-20394) in Combination With Rituximab in Patients With Relapsed/Refractory Indolent NHL [Phase 1, Phase 2]
Clinical trial update for a Phase 1/2 study of linperlisib in combination with rituximab in relapsed/refractory indolent non-Hodgkin lymphom…
-
CLINICAL_TRIALS trial_result · 2025-05-16Clinical Trial Update: Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A completed Phase 1/2 trial evaluating dendritic cell therapy with cryosurgery and pembrolizumab in various Non-Hodgkin lymphoma subtypes, w…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS other · 2025-05-16Clinical Trial Update: Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies [Phase 1]
Phase 1 clinical trial evaluating Genetically Engineered Anti-CD19/CD20/CD22 CAR T-cells for relapsed or refractory lymphoid malignancies; c…
-
CLINICAL_TRIALS trial_result · 2025-03-20Clinical Trial Update: Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies [Phase 2]
This Phase 2 trial investigates reduced-intensity chemotherapy and radiation therapy before donor stem cell transplantation for various hema…
-
CLINICAL_TRIALS research · 2025-01-06Clinical Trial Update: MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma [Phase 2]
A Phase 2 trial exploring MRD-guided de-intensification of Bendamustine plus Rituximab for indolent non-Hodgkin lymphoma; the study is curre…
-
CLINICAL_TRIALS trial_result · 2024-12-11Clinical Trial Update: Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) [Phase 3]
A Phase 3 trial evaluated copanlisib in combination with standard immunochemotherapy for relapsed indolent non-Hodgkin lymphoma. The study w…
-
CLINICAL_TRIALS trial_result · 2024-10-24Clinical Trial Update: A Study to Learn More About Copanlisib Treatment Patterns in People With Indolent Non-Hodgkin Lymphoma, a Type of Cancer That Grows and Spread Slowly and Develops in the Lymphatic System (a Part of Immune System) in Taiwan Under Real-word Conditions
This clinical trial update describes real-world patterns of copanlisib use in people with relapsed or refractory Indolent Non-Hodgkin Lympho…
-
CLINICAL_TRIALS trial_result · 2024-09-19Clinical Trial Update: A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma [Phase 2]
This Phase 2 study comparing two intermittent dosing schedules of duvelisib in indolent non-Hodgkin lymphoma has completed, with results pos…
-
FDA approval · 2024-02-26FDA Approved: BENDAMUSTINE HYDROCHLORIDE — Supplemental Application (Baxter Healthcare Corporation)
FDA approved a supplemental application for bendamustine hydrochloride (Baxter Healthcare Corporation) under NDA 216078.
-
CLINICAL_TRIALS trial_result · 2023-11-18Clinical Trial Update: Phase III Copanlisib in Rituximab-refractory iNHL [Phase 3]
Phase III trial update for copanlisib in rituximab-refractory indolent non-Hodgkin lymphoma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-05-12Clinical Trial Update: IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma. [Phase 2]
Phase 2 trial update examining IBI376 plus rituximab in untreated indolent lymphoma (non-Hodgkin lymphoma).
-
CLINICAL_TRIALS trial_result · 2023-04-14Clinical Trial Update: A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma [Phase 3]
Phase 3 trial evaluating ibrutinib in combination with either bendamustine/rituximab or rituximab-based regimen in previously treated indole…
-
CLINICAL_TRIALS trial_result · 2023-03-31Clinical Trial Update: First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 Years [Phase 2]
Phase 2 trial update on first-line therapy for advanced Follicular Lymphoma in patients under 60 not eligible for standard immunochemotherap…
-
CLINICAL_TRIALS trial_result · 2022-01-04Clinical Trial Update: Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) [Phase 3]
Phase 3 trial evaluating Copanlisib in combination with Rituximab in relapsed indolent B-cell non-Hodgkin lymphoma has completed with result…
-
CLINICAL_TRIALS trial_result · 2021-09-29Clinical Trial Update: Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial evaluating lenalidomide in combination with rituximab for various stage III/IV indolent non-Hodgkin lymphoma subtypes; study c…
-
CLINICAL_TRIALS trial_result · 2021-08-12Clinical Trial Update: Efficacy and Safety Study of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor in Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (iNHL) [Phase 2]
Phase 2 study of Tenalisib (RP6530), a dual PI3K δ/γ inhibitor, in relapsed/refractory indolent non-Hodgkin's lymphoma; study completed with…
-
CLINICAL_TRIALS trial_result · 2021-05-07Clinical Trial Update: Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma [Phase 2]
Phase 2 trial evaluating PCI-32765 (acalabrutinib) in combination with obinutuzumab for untreated indolent non-Hodgkin lymphoma.
-
CLINICAL_TRIALS trial_result · 2021-03-19Clinical Trial Update: Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL) [Phase 1]
Phase 1 trial in Japanese participants assessing safety, tolerability, and pharmacokinetics of idelalisib in relapsed or refractory indolent…
-
CLINICAL_TRIALS trial_result · 2021-03-18Clinical Trial Update: Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia [Phase 1]
Phase 1 study evaluating idelalisib in combination with various chemotherapeutic, immunomodulatory agents, and anti-CD20 antibody in relapse…
-
CLINICAL_TRIALS withdrawal · 2021-03-17Clinical Trial Update: A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) [Phase 3]
Phase 3 trial BRAVURA evaluating duvelisib with rituximab and bendamustine versus placebo in indolent non-Hodgkin lymphoma was withdrawn.
-
CLINICAL_TRIALS trial_result · 2021-01-07Clinical Trial Update: A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial evaluating Rituxan (rituximab) with beta-glucan PGG in relapsed indolent B-cell non-Hodgkin lymphoma has completed, with resul…
-
CLINICAL_TRIALS trial_result · 2020-11-23Clinical Trial Update: Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies [Phase 1]
Phase 1 trial evaluating anti-CD20 radioimmunotherapy before chemotherapy and stem cell transplant in high-risk B-cell malignancies; trial s…